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A B S T R A C T
Despite some encouraging findings for the treatment of neuropathic pain in patients with spinal cord injury
(SCI), transcranial direct current stimulation (tDCS) directed to the primary motor cortex (M1) has faced some
mixed results. Prior to translating this technology to clinical care, consistent results and durable effects need to
be found. We, therefore, aimed to assess the direct and long-term effects of tDCS on pain following SCI.
We performed a two-phase randomized sham-controlled clinical trial where patients received 5 days of tDCS
followed by at 3-month follow-up period (Phase I); then, Phase II consisted of 10 days of tDCS with an 8-week
follow-up period. We assessed the level of pain with the Visual Analogue Scale (VAS). Patients’ quality of life
and life satisfaction were also evaluated.
33 patients were enrolled in Phase I and 9 in Phase II. We observed a treatment effect at 1-week follow-up
for Phase I and at 4-week follow-up for Phase II. The overall level of pain was significantly lower for the active
group, as compared to sham, in Phase II.
Our exploratory study shows that tDCS does seem to be a promising tool to manage pain in patients with
SCI and repeated stimulation sessions are needed to induce long-lasting effects. Based on our protocol, it appears
that adding a second treatment period could induce long-lasting effects.
Clinicaltrials.gov identification number: NCT01599767
1. Introduction
Chronic sublesional neuropathic pain in patients who suffered a
spinal cord injury (SCI) is a major health problem that causes signifi-
cant burden and cost to both the individual and society. Following a
SCI, nearly 40% of people report neuropathic pain that is often refrac-
tory to medications [1,2]. Therefore, there is a crucial need to develop
novel pain therapeutic approaches to manage pain. Chronic sublesional
neuropathic pain in SCI results from a dysfunction of cortical areas as-
sociated with sensory and pain processing, which become dysfunctional
after SCI due to diminished input from peripheral sensory systems [3].
Evidence suggests that the resulting chronic pain is associated with
the phenomenon of central sensitization involving a large neural net-
work that includes limbic structures, such as the anterior cingulate cor-
tex, hippocampus and amygdala, and thalamic nuclei [4–6]. However,
the precise mechanisms leading to central sensitization in SCI are not
yet understood. It is known that increased spinal cord excitability leads
to enhanced activity in pain-related brain structures, including the sen-
sorimotor cortex [7]. The development of central sensitization is one
of the reasons that could explain why standard treatments for chronic
pain in SCI are not effective in alleviating pain since they do not tar-
get the modulation of pain-related dysfunctional brain areas. Therefore,
one strategy to mitigate pain is targeting cortical area linked to pain cir-
cuitry. In this study, we propose to use a technique of cortical modu
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lation – transcranial direct current stimulation (tDCS) – and chose the
primary motor cortex (M1) as the main neural target.
tDCS is a simple method that modulates brain activity of these pain
processing centers. It is based on the application of a weak direct cur-
rent to the scalp, which runs between an anode and cathode electrode,
inducing modulation of cortical excitability under the stimulated area
[8,9]. Robust and extensive basic science research has demonstrated the
effects of tDCS and many studies have confirmed that anodal stimula-
tion increases cortical excitability while cathodal stimulation decreases
it [8,10,11]. From a clinical perspective, anodal tDCS of the primary
motor cortex (M1) can induce clinically significant pain relief in chronic
pain syndromes [7,12–16]. In a previous study, our group has tested the
effects of tDCS in SCI patients suffering from neuropathic pain, showing
that 5 consecutive daily sessions of M1 tDCS significantly reduced level
of pain after the end of the stimulation sessions but not when reassessed
at 2-week follow-up [7]. Other studies, investigating the neural corre-
lates of tDCS in SCI, or the combination of tDCS with adjuvant ther-
apy, have found similar results on pain intensity reduction following the
stimulation of M1 [17–20].
We chose M1 as the target given its effects as central pain modula-
tion [21]. Several studies have shown that M1 stimulation leads to local
and distant effects that result in pain reduction. For instance, stimulat-
ing M1 may counteract the lack of inhibition from M1, that could also
be associated with pain reduction [22,23]. In addition, it also leads to
changes in thalamic and cingulate activity [24], known to be related to
pain processing.
Contrasting with these findings, other tDCS trials indicate there were
no significant differences in pain reduction following active and sham
stimulation [25]. In addition, nothing is known about the effects of tDCS
on quality of life in people with sublesional neuropathic pain due to
SCI. Finally, the clinical effects of a prolonged regimen of tDCS have not
been tested. These gaps in knowledge must be addressed prior to trans-
lating this technology to clinical care.
Therefore, in this exploratory study, we aimed to assess the direct
and long-term effects of tDCS on sublesional neuropathic pain follow-
ing SCI. We hypothesize that active tDCS will have a greater decrease
in pain level (as measured with the Visual Analogue Scale – VAS – for
pain) as compared to sham tDCS. Given that we wanted to study the
immediate and late effects in a 1-year study, we broke the protocol in
two phases. All patients enrolled for 5 days of tDCS with a 3-month fol-
low-up period. After this period, patients could continue to the second
phase, consisting of 10 days of tDCS with an 8-week follow-up period.
Our secondary outcomes were to test the effects of tDCS on patients’
quality of life and life satisfaction, as measured by the Patient Health
Questionnaire (PHQ-9) and the Satisfaction with Life Scale (SWLS).
2. Methods
2.1. Study outline
Phase I: patients received 5 sessions of tDCS, once a day for 5 days.
Assessments were performed at baseline, at the end of the 5 stimulation
sessions, at 1-week and 3-month follow-up.
Phase II: patients received 10 sessions of tDCS, once a day during
weekday for 2 weeks (same allocation group as Phase I). Assessments
were performed after 5 and 10 stimulation sessions and at 2, 4 and
8-week follow-up.
Note that Phase II begun at the end of the 3-month follow-up for
Phase I.
2.2. Study participants
We recruited subjects, both men and women aged 18 or older with
SCI (based on the American Spinal Injury Association (ASIA) Impair-
ment Scale performed at time of enrollment) who had ongoing suble-
sional neuropathic pain that is moderate or severe in nature (average
VAS scale score of 4 or greater at time of enrollment). Exclusion cri-
teria were as follows: 1. active alcohol or drug dependence, as self-re-
ported; 2. a history of bipolar disorder or psychosis, as self-reported;
3. inability to travel to the study site; 4. current use of any of the fol-
lowing anti-epileptic medications or dopaminergic medications known
to reduce or inhibit the benefits of tDCS treatment: carbamazepine,
oxcarbazepine, phenytoin, ropinirole (Requip), pramipexole (Mirapex),
and cabergoline (Dostinex); 5. the following contradictions to tDCS: im-
planted metal plates in the head, or deep brain stimulator (spinal cord
implants, including baclofen pumps, are not a contraindication as cra-
nial currents do not reach the spinal cord); 6. pregnancy at time of en-
rollment; 7. current use of ventilator.
Written informed consents were obtained from all patients accord-
ing to the declaration of Helsinki. The study was approved by the in-
stitutional reviewed board of Spaulding Rehabilitation Hospital, Boston.
Clinicaltrials.gov registration number: NCT01599767
2.3. Assessments
We used the Visual Analog Scale (VAS) Pain scale, a simple 10- point
scale (0 = “no pain”, 10 = “pain as bad as you can imagine”), to mea-
sure patients’ worst pain and least pain, average level of pain and pain
at present time.
The Satisfaction with Life Scale (SWLS) assessed patients’ happiness
with current quality of life [26,27].
The Patient Health Questionnaire (PHQ-9) evaluated patients’ qual-
ity of life through mental state [28].
2.4. Transcranial direct current stimulation (tDCS)
Direct current was transferred by a saline-soaked pair of surface
sponge electrodes (35 cm⁠2) and delivered by a battery-driven, constant
current stimulator (Soterix Medical, New-York). The anodal electrode
was placed over the primary motor cortex (M1), contralateral to the
most painful side, and the cathodal electrode was placed over the oppo-
site supra-orbital area. The duration of stimulation was 20 min at 2 mA
with a ramp-up and ramp-down of 30 s, as previously described [7].
For the sham condition, the stimulation was applied for 30 s with the
same ramp-up and down, to mimic the active condition. It has been
shown that subjects usually cannot detect active from sham conditions
using these parameters [29]. The device we used allows the delivery of
both active and sham stimulation, and all stimulation sessions were per-
formed by a researcher who was not involved in any of the assessments,
allowing a double-blind procedure.
Both treatment groups received 5 consecutive days of tDCS (phase I)
with a 3-month follow-up period. If the participant agreed to take part
in the Phase II of this trial, they received an additional 10 sessions of
tDCS with an 8-week follow-up.
2.5. Statistical analysis
Differences in baseline values between the two stimulation condi-
tions were analyzed with a Student t-test for continuous variables and
with Chi-square tests for dichotomous variables.
All analyses were conducted according to the principle of inten-
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To determine the difference between the groups in experiencing pain
(VAS − primary outcome), a multiple linear regression model was used.
To control for baseline difference in level of pain between the two
groups we added the baseline measure to the model. We tested other
potential confounders such as age, time since injury and gender using
a Pearson correlation. If the correlation between the covariate and pain
improvement was significant, the covariate was added to the model.
A similar model was conducted for each of our secondary outcomes
(PHQ9 and SWLS).
Phase II: The same model was used for all variables. As exploratory
analyses, to look at the cumulative effect of the treatment, we also com-
pare the area under the curve (AUC) for both interventions. The AUC for
each treatment group (active and sham) at each time point was deter-
mined using the trapezoidal rule, and the difference in the AUC between
active and sham treatment was compared using a Student t-test.
Two-tailed P values <0.05 were considered statistically significant
in all cases.
All statistical analyses were performed using STATA (StataCorp
2013. StataCorp LP, College Station, TX).
3. Results
33 patients were randomized to receive either active (n = 16) or
sham tDCS (n = 17). Patients flow-chart is presented in Fig. 1.
9 patients were enrolled in the second phase of the study. In phase
II, all patients completed all study visits.
Baseline comparisons between stimulation conditions showed no
significant a priori differences except for gender (Chi-square: 4.90;
p = 0.009).
None of the confounders (i.e., age, time since injury and gender)
reached the significance threshold; therefore, they were not added to
the model.
3.1. Phase I
Primary outcome: The linear regression models showed that the
group status (active versus sham) was associated with changes in VAS
scores at 1-week follow-up for average (p = 0.003) and least
(p = 0.043) pain (see Fig. 2 and Table 2). Patients’ individual data can
be found in supplementary Table 1.
Secondary outcomes: No significant changes were found for the
PHQ9 nor for the SWLS at any time points (all p-values >0.05–see sup-
plementary Table 2).
Descriptive analyses: When comparing patients suffering from severe
pain (VAS average >5) with patients with lower level of pain, we ob-
served a higher pain decrease in patients with VAS scores at baseline
higher than 5 (see Table 3).
3.2. Phase II
When comparing characteristics (i.e., age, time since injury, side of
stimulation, gender) and treatment allocation (active or sham) of pa-
tients enrolled in phase I with patients enrolled in Phase II, no signifi-
cant differences were found (Table 1).
The linear regression models showed that the group status (active
versus sham) was associated with VAS changes for VAS average at
4-week follow-up (p = 0.016).
No significant changes were identified for any of the other outcomes
at any time points (VASs, PHQ-9 and SWLS).
When comparing the AUC between the two interventions, we ob-
served a significant higher AUC for sham (i.e., higher VAS scores)
for VAS average (p = 0.026) and VAS least (p = 0.011). None of the
other scales demonstrated a significant difference between active and
sham conditions.
3.3. Safety
All study participants well tolerated tDCS sessions. The majority re-
ported a mild-to-moderate tingling or itching sensation during both ac-
tive and sham stimulations. No unexpected adverse effects were ob-
served.
4. Discussion
In this randomized controlled clinical trial, we found that 5 sessions
of tDCS can reduce the level of pain in patients with SCI. However, the
effects were not noticed directly after the end of the stimulation ses-
sions but at 1-week follow-up. For patients who continued to the sec-
ond phase of this study, the overall level of pain remained significantly
lower in patients who received the active treatment as compared to pa-
tients allocated to the sham intervention.
4.1. tDCS to prevent the mechanisms of chronic pain
Managing pain in patients with SCI is critical since neuropathic pain
has been identified as the primary factor for poor quality of life, leading
to depression, loss of employment and reduced productivity [30–32].
The analgesic effect of M1 tDCS could be related to the mechanisms of
chronic pain in patients with SCI, such as central sensitization and de-
ficient inhibitory process, as observed in previous tDCS studies focusing
on pain management [33–35]. In a previous longitudinal study, the ma-
jority of SCI patients reporting chronic pain had their pain onset within
six weeks post-injury and 80% of them stated that their pain started on
the day of the injury [36]. There are extensive data showing that, by
decreasing acute pain, the chances to develop chronic pain are reduced
since the mechanisms of maladaptive plasticity are limited. In fact, hy-
peractivity within pain-related neural areas often precedes chronic pain;
and has been recently demonstrated [37,38]. Therefore, future longitu-
dinal trials should also evaluate the long-term effects of tDCS on acute
patients suffering from neuropathic pain after a SCI, or as a prophylactic
treatment. By acting in an earlier phase of the disease, tDCS could also
limit the pathological reorganization of the pain matrix which leads to
the occurrence of neuropathic pain.
4.2. Delayed tDCS effects on pain reduction
The low number of sessions (i.e., 5) may have prevented larger tDCS
effects in the present study. However, we did find significant delayed
tDCS-related effects, which confirms our hypothesis that M1 tDCS ef-
fects on pain reduction are driven by changes in cortical plasticity, and
not only related to direct and short-lasting increase in cortical excitabil-
ity. Long-lasting changes in plasticity, as observed in this study, have
been seen before in other conditions using tDCS [7,46,47]. Even con-
sidering the delayed effects of tDCS observed in this study, it is impor-
tant to stress that repeated exposure to tDCS is needed to induce last-
ing plastic changes promoting synaptic strengthening of the structures
targeted, especially in a chronic population. It is conceivable that these
patients have important plastic changes in pain-related neural networks.
Hence, this might explain why we only observed a delayed effect af-
ter the end of stimulation. Delayed tDCS-response has been observed
in previous studies assessing the effect of tDCS on pain and MEP in
patients with migraine and elderly people, respectively [48,49]. tDCS
mechanisms are related to its influence on sodium and calcium chan-
nels opening and NMDA receptors excitability [50], while long-last-
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Fig. 1. Flow chart of participant enrollment, randomization and follow-up (based on the CONSORT Flow Diagram: http://www.consort-statement.org/consort-statement/flow-diagram/).
namely long-term potentiation (LTP) and long-term depression (LTP or
LTD) [51–53]. Structural, functional and connectivity alterations at the
cortical level have been described in patients with SCI, especially in the
somatosensory cortex, consequently to the injury itself, as well as a re-
sult of the lack of sensory and motor inputs [54–56]; these changes be-
ing related to neuropathic pain [57]. Therefore, it is possible that pa-
tients with SCI sustain a decline in plasticity mechanisms as compared
to those observed in healthy subjects, and therefore, tDCS related neu-
roplastic mechanisms may occur in a delayed manner.
Two studies on tDCS in patients with SCI are worth mentioning to
discuss. One of them investigated the effect of 5 sessions of tDCS on
pain level in a small sample of patients with SCI (n = 10); no differ-
ence between active and sham tDCS was observed [25]. The authors
explained that lack of effects is likely due to refractoriness of pain and
duration of disease since most of the patients enrolled had injury dura-
tions of 10 or more years. In addition, the limited number of sessions
and small sample size, may not have been sufficient to observe signif-
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Fig. 2. Change in visual numerical scale for pain for sham (grey lines) and active tDCS (black lines) measured at baseline, immediately after 5 days of tDCS, at 1 week and 3-month
follow-up for phase I and at baseline, after 5 and 10 sessions of tDCS and at 2, 4 and 8-week follow-up. Bars represent the standard deviation. *represent the significant difference between
the active and sham groups.
Table 1
Clinical and Demographic Characteristics . SD = standard deviation; tDCS = transcranial direct current stimulation; VAS = visual analogue scale. ⁠+ side of stimulation was based on the
most painful area. *p-value comparing difference between patients’ demographic characteristic enrolled in Phase I and in phase II.
Active tDCS Sham tDCS P values (active/sham) Group P values* (PhI/PhII)
Phase I (n = 33)
Number of subjects 16 17 33
Age (years, mean ± SD) 51.38 (±14.89) 51.00 (±10.11) 0.932 51.18 (±12.45)
Gender (Number of males – %) 15 (94%) 9 (53%) 0.009 24 (73%)
Side of stimulation ⁠+ (left hemisphere – %) 15 (94%) 15 (88%) 0.582 30 (91%)
Time since injury (years, mean ± SD) 5.81 (±6.27) 4.56 (±3.54) 0.481 5.17 (±5.01)
Level of pain at baseline (VAS, mean ± SD) 5.44 (±1.90) 6.06 (±2.01) 0.369 5.76 (±1.95)
Phase II (n = 9)
Number of subjects 6 3 9 0.333
Age (years, mean ± SD) 49.47 (±16.01) 47.67 (±3.54) 0.835 49.00 (±14.38) 0.653
Gender (Number of males) 6 (100%) 1 (33.33%) 0.023 7 (78%) 0.760
Side of stimulation ⁠+ (left hemisphere) 5 (83.33%) 3 (100%) 0.453 8 (89%) 0.855
Time since injury (years, mean ± SD) 7.67 (±9.50) 3.67 (±1.41) 0.370 6.33 (±8.14) 0.589
Level of pain at baseline (VAS, mean ± SD) 5 (±2.25) 4.33 (±1.53) 0.628 4.78 (± 2.05) 0.194
Table 2
Visual Analogue Scale (VAS) at all time points for active and sham tDCS, mean, standard deviation (SD), change from baseline (i.e, delta) and p-values of the treatment effect. Bold number
represent a significant p-value (p < 0.05).
Active Sham P value
Mean (SE) Delta − Mean (SE) Mean (SE) Delta − Mean (SE)
VAS average
Baseline 5.33 (0.49) / 6.05 (0.49) / 0.369
After stimulation 5.39 (0.61) 0.05 (0.30) 5.50 (0.40) −0.56 (0.32) 0.323
1-week follow-up 4.22 (0.59) −1.11 (0.56) 5.79 (0.45) −0.26 (0.63) 0.003
3-month follow-up 5.22 (0.54) −0.11 (0.85) 6.22 (0.51) 0.16 (0.68) 0.353
VAS present
Baseline 5.20 (0.70) / 6.00 (0.46) / 0.396
After stimulation 4.98 (0.76) −0.22 (0.35) 5.44 (0.59) −0.56 (0.30) 0.701
1-week follow-up 3.74 (0.69) −1.46 (0.71) 5.31 (0.43) −0.69 (0.52) 0.274
3-month follow-up 5.30 (0.61) 0.10 (1.10) 5.21 (0.47) −0.79 (0.70) 0.491
VAS least
Baseline 2.93 (0.64) / 4.41 (0.57) / 0.115
After stimulation 3.78 (0.66) 0.84 (0.43) 3.75 (0.42) −0.67 (0.50) 0.068
1-week follow-up 3.06 (0.62) 0.13 (0.66) 5.05 (0.57) 0.64 (0.76) 0.043
3-month follow-up 2.88 (0.44) −0.06 (0.85) 3.31 (0.52) −1.10 (0.79) 0.819
VAS worst
Baseline 7.33 (0.61) / 7.35 (0.44) / 0.976
After stimulation 5.92 (0.61) −1.41 (0.57) 6.89 (0.67) −0.48 (0.64) 0.534
1-week follow-up 5.91 (0.66) −1.42 (0.64) 7.27 (0.47) −0.08 (0.64) 0.239
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Table 3
Visual Analogue Scale (VAS average) at all time points (Phase I) for active tDCS, mean, standard deviation (SD), change from baseline (i.e, delta) for patients divided by their level of pain
(i.e, VAS average > or ≤5 at baseline).
Baseline Post active tDCS 1-week follow-up 3-month follow-up
Mean (SD) Mean (SD) Delta mean (SD) Mean (SD) Delta mean (SD) Mean (SD) Delta mean (SD)
VAS ≤ 5 3.88 (1.25) 4.13 (1.96) 0.25 (0.71) 3.29 (1.32) −0.58 (0.07) 5.57 (2.26) 1.69 (1.01)
VAS > 5 7.00 (0.76) 6.54 (1.98) −0.47 (1.23) 5.28 (2.81) −1.72 (2.05) 4.72 (1.86) −2.28 (1.11)
though the sample size was large (n = 135), did not show significant
differences between sham and active tDCS [58]. However, low back
pain is not a neuropathic pain and therefore the results cannot be di-
rectly translated to our findings. In addition, it is worth mentioning
that study did not include follow-ups to assess the long-lasting effects of
tDCS, since, directly after the end of the stimulation sessions, a new in-
tervention was applied. Therefore, the possible long-term effects of tDCS
were not directly investigated in that large randomized clinical trial.
Regarding the outcome measures, the data variability of pain scores
might have decreased the power for the analysis during the stimula-
tion period. In addition, it is well known that the VAS and other quality
of life scales (e.g., SWLS and PHQ-9) can be affected by patients’ ex-
pectations and therefore, may be a reason why a treatment effect was
only observed a 1-week follow-up. Indeed, patients’ expectations, or
the placebo effect, may have had an important component in the pre-
sent findings since both groups, active and sham, improved after the
first treatment session. However, the active group only demonstrated
tDCS-related improvements at follow-up. It is, therefore, essential to de-
fine new clinical measures requiring more objective reports of pain from
patients, such as task-related outcomes to disentangle the treatment ef-
fect from the placebo effect.
4.3. Long-lasting effects of tDCS
In the second phase of the present trial (Phase II: 10 tDCS sessions 3
months subsequently Phase I), we did not observe any significant treat-
ment effect at any time point, except for the VAS average at 4-week fol-
low-up, which is in line with the results we observed in Phase I. The
lack of significant results can also be explained by the small sample size
since only 9 patients enrolled in Phase II, 6 in the active group and 3 in
the sham group. Therefore, we looked at the AUC to evaluate the cumu-
lative effect of tDCS during these 2 weeks of stimulation with an 8-week
follow-up period. For both VAS average and VAS least we found that
the active group had significant lower AUC as compared to the sham
group, suggesting overall lower VAS scores. When looking at the results,
the active group demonstrated a consistency in lower VAS scores, while
the sham group presented higher variability in level of pain. This obser-
vation highlights the long-term effects of tDCS in maintaining low level
of pain as compared to the sham intervention. As abovementioned, sev-
eral studies have highlighted the need for repeating the number of tDCS
sessions (10–20) to induce long-lasting and clinically relevant effects.
In the present study, even with a limited sample size, we demonstrated
that adding a second phase of 10 stimulations sessions can help main-
taining the benefits induced by tDCS.
4.4. Adherence to extended tDCS protocol
It has been shown that a minimum of 10–20 sessions of tDCS need
to be performed in order to induce relevant clinical improvements
[39–42]. However, in clinical trials involving patients with severe dis-
abilities, such as SCI as in the present study, we experienced a high
rate of drop-out which limits the power of clinical results. Conducting
clinical trials requesting daily visits in a research facility with people
with mobility problems represents a challenge and may influence sub-
jects’ poor adherence. We investigated the issue of poor adherence in
this specific SCI trial, showing that people with higher levels of pain are
more motivated to travel to the research facility for multiple tDCS ses-
sions [43]. As patients with more severe level of pain had higher pain re-
duction following tDCS, it may be possible that treatment efficacy could
have impacted adherence too. This is particularly true for patients with
pain symptoms for which compliance is a burden [44]. Strategies to im-
prove patients’ compliance are needed to obtain more accurate data that
could be translated to clinical practice. Indeed, even though we used a
multiple imputation model, it may not exactly reflect the results that
would have been obtained with a fully adherent population. In addition,
patients who did not complete the entire protocol, may not have bene-
fited from the effects of tDCS on pain reduction. Therefore, it is essen-
tial to develop strategies to improve patients’ adherence to, (i) collect
exact data and (ii) determine the exact proportion of patients respond-
ing to tDCS, as well as the amount of pain relief tDCS can induce. One
solution that has been tested in patients with Parkinson Disease is the
use of a home-based device with close supervision by researchers and
clinicians [45]. In this study, the compliance was as high as 100% (for
a total of 40 sessions) and no adverse events occurred, showing that re-
motely supervised tDCS could be a valuable option to reduce the num-
ber of drop-outs, in addition to represent a step forward in the clinical
translation of tDCS.
4.5. Patients with higher pain levels seem to respond better to tDCS
Even though the analyses performed were descriptive, it seems that
tDCS induces stronger pain reduction in patients with higher pain level.
Indeed, when looking at the results for patients with VAS scores above
5, pain reduction was higher as compared to patients with lower level
of pain (see Table 3). It is well known that tDCS works better when it
targets a behavior or a function that has some room to improve. For
instance, tDCS can enhance hand motor function when applied over
the non-dominant hemisphere but not when the dominant motor cor-
tex is stimulated [63], this is what is called the ceiling effect. For pa-
tients with lower pain level, it is possible that the sensorimotor cortex
does not show pathophysiological modification or is less alerted when
compared to patients with higher pain intensity. Indeed, several neu-
roimaging studies have demonstrated the correlation between pain in-
tensity and degree of abnormal activity and connectivity within areas
of the pain matrix in various chronic pain syndromes [60,64,65]. Fu-
ture research to identify biomarkers and predictors of tDCS response
could help to identify who and why some patients could benefit from
this treatment, as well as to develop a patient-tailored stimulation pro-
tocol.
4.6. How to improve the effects of tDCS?
The combination of tDCS with pharmacological agents could also
be a way to increase pain-related effects of tDCS, in term of dose re-
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induced by pregabalin intake was related to a decrease in connectivity
between the default mode network (DMN) and the insular cortex [59],
which is hyperactivated in patients with chronic pain [60,61]. In an-
other neuroimaging study (i.e., functional MRI) evaluating the effects of
M1 tDCS in patients with fibromyalgia, the authors demonstrated that
tDCS induced a significant reduction in functional connectivity between
the thalamus and the supplementary motor area, the medial prefrontal
cortex and the cerebellum [62]. It can be hypothesized that combining
two treatments acting on the reduction of hyperactivity in pain-related
cortical and subcortical regions could lead to higher and longer pain de-
crease.
4.7. Limitations
There are several limitations of this study that need to be considered
when interpreting the results. Firstly, these findings must be considered
preliminary since we performed exploratory analyses, as a consequence
of the limited size of the population enrolled in this study. In addition,
the descriptive analyses showed that patients with higher level of pain
seems to respond better to tDCS. However, due to the small sample size,
we could not perform further sub-group analyses. The high degree of
variability within the groups (e.g., for gender or initial level of pain)
is another limitation that need to be considered and that may have in-
fluenced the results. Future large sample size controlled clinical trials,
should be performed to validate our findings, and provide more details
regarding the subpopulation of patients that may benefit the most of
tDCS. Finally, another important limitation, is the high rate of drop-out,
which could have biased our findings for Phase I, even though we used
a multiple imputation model to replace missing data.
5. Conclusion
In conclusion, tDCS seems to be a promising tool to manage pain in
patients with SCI and repeated stimulation sessions are needed to induce
long-lasting effects. In fact, it is clear that parameters of stimulation may
not be optimal yet. Based on our protocol, it appears that adding a sec-
ond treatment period could help maintain the effects of tDCS. There-
fore, future trials evaluating the impact of tDCS on pain management
should investigate the effect of intermittent tDCS sessions (e.g., 5 daily
(or more) tDCS sessions, once a month for 6 months) to better character-
ize the number of sessions needed to induce sustainable effects. Finding
ways to limit the number of drop-outs is another challenge we need to
tackle particularly if we want to investigate tDCS long-term effects. Fi-
nally, patients with higher level of pain tend to respond better to tDCS
as compared to patients with lower pain intensity.
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